Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease

Authors:

Abstract
Erdheim-Chester disease (ECD) is an uncommon histiocytic disorder that is considered a hematologic cancer.1 Because of the rarity of the disease, there are limited data on treatment options and their efficacy. Historically, interferon alfa has been used with variable efficacy, albeit at the cost of adverse effects.2 This limitation has led to the use of other agents in an attempt to find more efficacious and less toxic therapies. Cladribine (2-chloro-2′-deoxyadenosine) is an antimetabolite approved by the US Food and Drug Administration for the treatment of hairy cell leukemia. It has also been shown to have activity in other lymphoid cancers (chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, and certain low-grade lymphomas), as well as Langerhans cell histiocytosis. Increasing numbers of case reports demonstrate activity of cladribine in the treatment of ECD.3-10 However, contemporary trial or prospective data are lacking to help discern the response rate and outcomes with this agent. In this study, our objective was to assess the efficacy of cladribine in the treatment of ECD.

This publication has 15 references indexed in Scilit: